The sale is a win for Bristol-Myers Squibb, which is working to overcome antitrust concerns to secure approval for its $74 billion acquisition of Celgene.
Bristol-Myers said in June it would sell Otezla to ease concerns raised by the Federal Trade Commission because of a competing treatment it is developing.
Otezla had $1.61 billion in sales last year. Amgen expects sales from the drug to increase over the next five years.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
